RxDoctor Payments Data

Aaron Morgan, MD

Family Medicine · Brewton, ALNPI 1932391661

Payments from drug & device makers

$518in general payments, 2019–2025

Across 25 payments — averaging $20.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$129
  • Galt Pharmaceuticals, LLC$102
  • Pfizer$48
  • Indivior Inc.$41
  • Exact Sciences$39
  • GSK$28
  • plus $132 from 7 others

What the payments were for

  • Travel & lodging$194%
  • Food & beverage$49996%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$518 in reported general payments places this provider in the 45th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$76,919
Medicare patients
321
Services billed
1,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin157$157,579
EliquisApixaban152$143,899
MounjaroTirzepatide100$113,968
LinzessLinaclotide128$109,326
OzempicSemaglutide64$80,481
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,886$61,388
XareltoRivaroxaban40$47,250
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$42,391
VraylarCariprazine Hcl28$41,038
FarxigaDapagliflozin Propanediol48$40,809
TrulicityDulaglutide17$39,688
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$35,794
EntrestoSacubitril/Valsartan39$29,439
Breo ElliptaFluticasone/Vilanterol42$28,783
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl119$22,667

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Vraylar, Ubrelvy$129$171,982182 claims
Lilly USA, LLCMounjaro, Trulicity$13$153,657117 claims
PfizerEliquis$48$143,899152 claims
GSKTrelegy Ellipta, Breo Ellipta$28$64,57778 claims
Indivior Inc.Suboxone$41$10,62414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Brewton

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →